---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-041591"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:51:45.263353+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences reports Q2 net loss of $76M, cash $805M; appoints Nicole Lambert to board

## Summary
- Net loss $76.0M for Q2 2021 vs $45.1M in Q2 2020; six-month net loss $148.6M.
- Collaboration revenue $9.5M in Q2 2021 vs $1.8M; R&D expenses $68.8M (up from $35.7M).
- Cash and investments $805.1M as of June 30, 2021 vs $735.1M at Dec 31, 2020; funded at least through 2023.
- Appointed Nicole Lambert to Board of Directors, President of Myriad Genetic Laboratories.
- Pipeline: HIF-2α inhibitor AB521 enters clinic in Q4 2021; domvanalimab combination data promising; randomized ARC-8 enrollment to complete by year-end.

## SEC filing metadata
- accession: 0001564590-21-041591
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/0001564590-21-041591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/rcus-8k_20210803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-041591
- JSON: https://secwatch.observer/filing/0001564590-21-041591.json
- Plain text: https://secwatch.observer/filing/0001564590-21-041591.txt

## Key facts
- Executive change
  Nicole Lambert was appointed as Director at Arcus Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/0001564590-21-041591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.